Breast Cancer Resistance to Cyclophosphamide and Other Oxazaphosphorines
Abstract
Cyclophosphamide, mafosfamide and 4-hydroperoxycyclophosphamide are antineoplastic agents collectively referred to as oxazaphosphorines. Each of these is a prodrug, i.e., per se, without cytotoxic activity. Salient features of the metabolic activation of oxazaphosphorines are presented. Oxazaphosphorines are clinically effective; they play a lead role in the treatment of breast cancer until resistant subpopulations become the dominant population. An understanding of how resistance to these agents is effected would likely to be of value because measures may then become apparent as to how to reverse, and/or prevent, it. It is this understanding which is the overall objective of our first-generation investigations.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1996
- Accession Number
- ADB221437
Entities
People
- Norman E. Sladek
Organizations
- University of Minnesota